Tanshinones, including tanshinone IIA, tanshinone I and dihydrotanshinone I, have been reported to treat liver fibrosis by inhibiting the activation of HSCs, regulating PI3K/Akt signaling pathways, disrupting the YAP /TEAD2 complex, and stimulating autophagy (Liu and Huang, 2014; Ge et al., 2017; Shi et al., 2020). Here, AKT1 is linked to Hepatic fibrosis.